If you have been reading about GHRH analog and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-11-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH analog, not a steroid |
| Backbone length | 29 amino acids | Based on GRF(1-29) |
| Substitutions | Four positions | D-Ala2, Gln8, Ala15, Leu27 |
| Appearance | White to off-white powder | Typical lyophilized research material |
| Common synonyms | Modified GRF(1-29) | Usage varies between sources |
Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.
Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Inquiries sent to the IDF regarding the experiences of these health care workers received a statement from a spokesperson that did not directly confirm whether investigations into the shootings of preteen children had been conducted or if any soldiers faced disciplinary action for firing at them. In response to claims alleging that the report was based on "fabricated evidence", The New York Times issued a statement defending the integrity of the piece, emphasizing that it had undergone rigorous editing and verification, including consultations with experts and the use of supporting photographs, which they deemed "too horrific for publication." De Volkskrant interviewed 17 doctors who had volunteered during the Gaza war. Fifteen of them reported seeing children with "a single gunshot wound to the head and/or chest." These doctors reported seeing 114 children injured this way. In response, former Commander of the Royal Netherlands Army Mart de Kruif told the paper, "If you're seeing a high number of gunshot wounds to the chest area and the head, that’s not collateral damage – that’s deliberate targeting." In one documented case, a girl was reportedly shot and killed while in her mother's arms. In June 2026, a 94-page report by the UN Independent International Commission of Inquiry on the Occupied Palestinian Territory concluded there were reasonable grounds to determine that Israeli forces directly targeted children in Gaza using snipers and quadcopter drones.
== Anatomy == The pericardium is a tough fibroelastic sac which covers the heart from all sides except at the cardiac root (where the great vessels join the heart) and the bottom (where only the serous pericardium exists to cover the upper surface of the central tendon of diaphragm). The fibrous pericardium is semi-rigid, while the serous pericardium is quite pliable. The same mesothelium that constitutes the serous pericardium also covers the heart as the epicardium, resulting in a continuous serous membrane invaginated onto itself as two opposing surfaces (over the fibrous pericardium and over the heart). This creates a pouch-like potential space around the heart enclosed between the two opposing serosal surfaces, known as the pericardial space or pericardial cavity, which is filled with a small amount of serous fluid to lubricate the heart's movements and cushions it from any external jerk or shock.
=== Schizophrenia === Early evidence suggests sarcosine is an effective and well-tolerated adjuvant to many antipsychotics except clozapine for the treatment of schizophrenia, showing significant reductions in both positive and negative symptoms.
Sources: en.wikipedia.org
The U.S. National Institute of Standards and Technology investigated the collapses of the Twin Towers and 7 WTC. The investigations examined why the buildings collapsed and what fire protection measures were in place, and evaluated how fire protection systems might be improved in future construction. The investigation into the collapse of 1 WTC and 2 WTC was concluded in October 2005 and that of 7 WTC was completed in August 2008. NIST found that the fireproofing on the Twin Towers' steel infrastructures was blown off by the initial impact of the planes and that had this not occurred, the towers likely would have remained standing. A 2007 study of the north tower's collapse published by researchers at Purdue University determined that since the plane's impact had stripped off much of the structure's thermal insulation, the heat from a typical office fire would have softened and weakened the exposed girders and columns enough to initiate the collapse regardless of the number of columns cut or damaged by the impact. The director of the original investigation stated that "the towers did amazingly well. The terrorist aircraft didn't bring the buildings down; it was the fire that followed. It was proven that you could take out two-thirds of the columns in a tower and the building would still stand." The fires weakened the trusses supporting the floors, making the floors sag. The sagging floors pulled on the exterior steel columns causing the exterior columns to bow inward.
=== Lawsuit === Fenn's work with electrospray ionization was at the center of a lawsuit pitting him against his alma mater and former employer, Yale University. His initial dispute with the university began in 1987, when he turned 70 – Yale's mandatory retirement age. Per university policy, Fenn was made an emeritus professor, which resulted in a reduction to his lab space. Emeritus professors at Yale are still provided with an office, but cannot conduct their own research, nor manage their own labs. In 1989, when Yale University inquired about the progress and potential about his electrospray work, he downplayed its potential scientific and commercial value. Fenn believed he had the rights to the invention under the Bayh–Dole Act. Fenn patented the technology on his own, and sold licensing rights to a company he partly owned – Analytica of Branford. In 1993, a private company seeking to license the use of electrospray technology traced its invention to Yale, when the university discovered that Fenn held the patent. Yale's policy regarding patents generated by faculty or students requires that a percentage of any royalties generated from the patent are used by the university to fund future research. They do not claim the rights to patents that are produced away from university facilities or not related to the researcher's "designated activities." Fenn claimed that he owned the technology because the work was completed after he had been forced to downsize at the university's mandatory retirement age.
=== Progestogenic activity === CPA is a highly potent progestogen. It is described as the most potent progestin of the 17α-hydroxyprogesterone group, being about 1,200-fold more potent than hydroxyprogesterone acetate, 12-fold more potent than medroxyprogesterone acetate, and 3-fold more potent than chlormadinone acetate in animal bioassays. Based on results in the animal bioassays, CPA has also been said to be the most potent progestin known, with 1,000 times the potency of progesterone. With oral administration in humans however, CPA is distinctly less potent as a progestogen than various other progestins such as the 19-nortestosterone derivatives. The effective dosage of CPA needed to inhibit ovulation by itself in women (i.e., to act as a contraceptive) is 1 mg/day, and the medication is marketed as a contraceptive (combined with low-dose ethinylestradiol) at a dosage of 2 mg/day. For comparison, the ovulation-inhibiting dosage of levonorgestrel is 50 μg/day. At the dosages typically used clinically, CPA is described as a "strong" and "powerful" progestogen. Its endometrial transformation dosage is 20 to 30 mg per cycle and its menstrual delay test dosage has been estimated to be less than 1 mg/day. CPA is not well-balanced in terms of its activities; relative to the progestogenic potency of CPA, its potency as an androgen receptor antagonist is quite weak. In order to take full advantage of its antiandrogenic activity, CPA must be administered at a dosage of 50 to 100 mg per day, which is 2 to 3 times the cyclical endometrial transformation dose per day.
11 January – A scrub fire breaks out in Kūaotunu in the Coromandel Peninsula, consuming 36 hectares (89 acres) by the following day. 12 January – Mayor of Hamilton Paula Southgate announces that she would not be running for a third term during the 2025 New Zealand local elections. 13 January: New Zealand and the United Arab Emirates sign a comprehensive economic partnership agreement, cutting tariffs on 98.5% of New Zealand exports to that country. 14 January – Deputy Police Commissioner Jevon McSkimming is suspended from duties due to a criminal investigation by the Independent Police Conduct Authority and the New Zealand Police. 16 January: Hundreds including Police Commissioner Richard Chambers attend the funeral of slain Nelson Police officer Senior Sergeant Lyn Fleming. Health New Zealand confirms a baby who died in November 2024 as the first death caused by whooping cough since a whooping cough epidemic was declared on 22 November 2024. 17 January – Minister of Māori Development Tama Potaka announces an overhaul of the Waitangi Tribunal's membership. 18 January: A pod of about 30 whales are stranded near Pākawau in Golden Bay / Mohua, prompting a response from local iwi, the Department of Conservation(DOC) and Project Jonah. A juvenile beaked whale is stranded and refloated at New Brighton, Christchurch. 19 January: Prime Minister Christopher Luxon implements a cabinet reshuffle, resulting in the replacement of Shane Reti as health minister by Simeon Brown, and the promotion of James Meager to the new position of Minister for the South Island.
Sources: en.wikipedia.org
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.
The original material included a linker that binds serum albumin. A later variant removed that linker to reduce the duration of action. Catalogs and papers did not consistently adopt separate names, so both remain widely labeled with the same term.
The amino acid sequence and the presence or absence of the linker group. Mass measured by spectrometry gives an independent check that separates the two forms.
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.